The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market. Revuforj ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...

The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

Syndax Pharmaceuticals recently announced the FDA approval of Revuforj (revumenib) for the treatment of relapsed or refractory acute leukemia in adult and pediatric patients one year and older. It is ...

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...